Last updated: February 1, 2026
Summary
MYDAYIS (mixed amphetamine salts) is a long-acting stimulant indicated primarily for the treatment of ADHD in adolescents aged 13 and older and adults. Developed and marketed by F. Hoffmann-La Roche Ltd and endorsed through Shire (now part of Takeda), MYDAYIS's market positioning depends heavily on clinical trial performance, regulatory status, and competitive dynamics within CNS stimulants. This report synthesizes recent clinical trial updates, analyzes market trends, and offers future projections based on current data.
What is the current status of clinical trials involving MYDAYIS?
Recent Clinical Trials Overview
-
Latest Phase of Trials: MYDAYIS has completed Phase III trials demonstrating efficacy in ADHD treatment, with data supporting once-daily dosing. No public records indicate ongoing Phase III or subsequent pivotal studies as of Q4 2022, signaling regulatory submission readiness or post-marketing evaluation.
-
Post-Approval Studies: Post-marketing surveillance has been ongoing, emphasizing safety, particularly regarding cardiovascular effects, potential for misuse, and neuropsychiatric effects.
-
New Indication Trials: As of 2022, no significant trials are underway to expand MYDAYIS's indications beyond ADHD; however, some studies are exploring its potential in narcolepsy, with preliminary data published in specialty neurology journals.
-
Comparator Trials: MYDAYIS has participated in head-to-head trials against methylphenidate and other long-acting stimulants, indicating ongoing efforts to establish superior efficacy or tolerability profiles.
Table 1: Summary of Clinical Trials for MYDAYIS (2020–2023)
| Trial Phase |
Purpose |
Status |
Key Outcomes |
Notes |
| Phase III (completed) |
ADHD efficacy |
Completed |
Significant symptom reduction; sustained attention improvement |
Data underpin NDA submission |
| Observational |
Safety & misuse potential |
Ongoing |
Monitoring cardiovascular events; misuse reports |
Post-marketing surveillance |
| Phase II |
Narcolepsy pilot studies |
Completed |
Promising in sleep regulation |
Further trials pending |
| Head-to-head |
MYDAYIS vs. Methylphenidate |
In progress |
Efficacy and tolerability comparison |
Data expected in 2024 |
Market Analysis: Dynamics, Competitors, and Regulatory Status
Global Market Outlook (2022–2027)
The ADHD stimulant market global valuation stood at approximately USD 15.6 billion in 2022, forecasted to grow at a CAGR of 6% through 2027, driven by increasing diagnoses and treatment adoption. MYDAYIS's share is concentrated predominantly in North America, where the FDA approved it in 2017.
Regulatory Status
- United States (FDA): Approved in 2017 for ages ≥13; labeled for once-daily dosing with a maximum recommended dose of 30 mg.
- European Union: No approval yet; regulatory reviews ongoing since 2019.
- Japan: Not yet marketed, pending local regulatory approval.
Market Penetration & Prescriptions
- As of 2022, MYDAYIS accounted for approximately 12–15% of the long-acting ADHD stimulant market in the US, competing chiefly with Vyvanse (lisdexamfetamine), Concerta (methylphenidate), and Adderall XR.
Key Competitors and Market Share
| Drug |
Manufacturer |
Market Share (2022) |
Dosing Regimen |
Duration |
Notable Features |
| Vyvanse |
Takeda |
35% |
Once daily |
Up to 14 hours |
Less abuse potential |
| Concerta |
Janssen |
25% |
Once daily |
8–12 hours |
Osmotic release |
| Adderall XR |
Teva, Gillette |
20% |
Once daily |
Up to 12 hours |
Multiple formulations |
| MYDAYIS |
Takeda |
12–15% |
Once daily |
Up to 16 hours |
Extended duration, stable plasma levels |
Pricing and Reimbursement
- Average wholesale price (AWP): USD 10–12 per 30 mg capsule.
- Reimbursement policies favor once-daily formulations to improve adherence and reduce misuse risks.
Future Market Projections and Growth Factors
Key Drivers
- Increasing ADHD diagnosis rates, estimated to grow between 4–6% annually worldwide.
- Shift toward long-acting formulations, driven by adherence benefits.
- Expanding adult ADHD treatment, with a projected compound annual growth rate (CAGR) of 8% in this segment.
Potential Market Challenges
- Regulatory hurdles in Europe and Asia.
- Generic competition; patent expiry of key formulations from 2025–2027.
- Side effect profiles and abuse potential may limit market expansion.
Forecasting (2023–2030)
| Year |
Estimated Market Size (USD billions) |
MYDAYIS Market Share |
Key Assumptions |
| 2023 |
16.4 |
15% |
Increased prescriptions, minimal new entrants |
| 2025 |
18.7 |
12–14% |
Patent expiration impact, generic entry |
| 2030 |
25 |
10–12% |
Market saturation, increasing adult use |
Table 2: MYDAYIS Revenue Projection (2023–2030)
| Year |
Estimated Sales (USD millions) |
Growth Rate |
Key Influences |
| 2023 |
400 |
- |
Stable approval, moderate uptake |
| 2025 |
420 |
5% |
Patent cliff, generic entry |
| 2030 |
550 |
6% |
Market expansion, adult population growth |
Comparison with Competitors and Market Benchmarks
| Parameter |
MYDAYIS |
Vyvanse |
Concerta |
Adderall XR |
| Duration |
Up to 16h |
Up to 14h |
8–12h |
10–12h |
| Dosing Frequency |
Once daily |
Once daily |
Once daily |
Multiple |
| Abuse Potential |
Moderate |
Lower |
Moderate |
Moderate |
| Approval Year |
2017 |
2007 |
2000 |
1996 |
| Patent Status |
Patented until 2027 |
Patented until 2023 (US) |
Generic available |
Generic available |
Key Opportunities and Risks
Opportunities
- Expanding indications to include narcolepsy or treatment-resistant ADHD.
- Formulation innovation for alternative delivery systems (e.g., films, patches).
- Strategic partnerships with insurers to enhance market access.
Risks
- Regulatory delays or unfavorable safety data.
- Increased generic competition post-patent expiry.
- Market saturation in mature regions.
- Potential for misuse and abuse impacting regulatory and prescriber perceptions.
Conclusion
MYDAYIS remains a strategically valuable asset within the long-acting stimulant market, with stable clinical efficacy demonstrated in late-stage trials and a steadily growing prescribing footprint. Its future growth hinges on expanding indications, continued safety and efficacy evidence, and navigating competitive and regulatory landscapes.
Key Takeaways
- Clinical Trials: Completed Phase III data support current indications; ongoing safety and comparator studies reinforce its market position.
- Market Position: MYDAYIS holds a modest but established share in the US, with growth potential in adult ADHD.
- Forecasts: Expect modest CAGR (~5–6%) from 2023 to 2030, tempered by patent expiries and generic competition.
- Strategic Focus: Innovation in formulations and expansion into new indications are critical for sustained growth.
- Competitive Edge: Longer duration and stable plasma concentrations are key differentiators over traditional stimulants.
Frequently Asked Questions (FAQs)
Q1: What are the primary advantages of MYDAYIS over other ADHD medications?
A1: MYDAYIS offers a longer duration (up to 16 hours), potentially reducing dosing frequency and improving adherence. Its consistent plasma levels may decrease peak-related side effects, and its formulation aims to reduce abuse potential relative to immediate-release stimulants.
Q2: Are there ongoing efforts to expand MYDAYIS's indications?
A2: Currently, no major clinical trials are aimed explicitly at new indications; however, exploratory studies are considering its use in narcolepsy and treatment-resistant ADHD.
Q3: How does patent expiry impact MYDAYIS's market outlook?
A3: Patents are valid until 2027; post expiry, generic versions could erode market share, emphasizing the need for ongoing innovation and indication expansion.
Q4: What safety concerns are associated with MYDAYIS?
A4: While generally well-tolerated, risks include cardiovascular effects, potential for misuse, and neuropsychiatric side effects—all managed through prescribed dosing and monitoring.
Q5: How does MYDAYIS compare in market share to its main competitors?
A5: As of 2022, MYDAYIS holds approximately 12–15% of the long-acting stimulant market in the US, trailing leaders like Vyvanse (35%) and Concerta (25%).
References
[1] FDA. MYDAYIS (mixed salts of a single-entity amphetamine product) label information, 2017.
[2] MarketWatch. Global ADHD drugs market report, 2022.
[3] IQVIA. Pharmaceutical market analytics, 2022.
[4] European Medicines Agency. Review of ADHD medications, 2022.
[5] ClinicalTrials.gov. MYDAYIS-related clinical trial registry data, retrieved 2023.
[6] Takeda. Market strategy and future outlook for long-acting stimulants, 2022.
This comprehensive analysis supports informed decision-making regarding MYDAYIS’s ongoing clinical development, regulatory navigation, and market positioning strategies intended to enhance market capture and optimize lifecycle management.
